PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.61%
Revenue growth 1.25-1.5x AVGO's 6.32%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
13.26%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-10.38%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-10.38%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-7.52%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.27%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-13.64%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-6.44%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
4.98%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-77.64%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-85.28%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
546.10%
10Y revenue/share CAGR 1.25-1.5x AVGO's 416.86%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
125.41%
5Y revenue/share CAGR similar to AVGO's 134.28%. Walter Schloss might see both companies benefiting from the same mid-term trends.
53.50%
3Y revenue/share CAGR at 75-90% of AVGO's 62.33%. Bill Ackman would expect new product strategies to close the gap.
897.28%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
12.51%
Below 50% of AVGO's 92.77%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
13.66%
3Y OCF/share CAGR under 50% of AVGO's 39.51%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
868.39%
Similar net income/share CAGR to AVGO's 869.72%. Walter Schloss would see parallel tailwinds or expansions for both firms.
179.23%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
318.68%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1311.12%
10Y equity/share CAGR above 1.5x AVGO's 862.23%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
176.58%
5Y equity/share CAGR is in line with AVGO's 165.61%. Walter Schloss would see parallel mid-term profitability and retention policies.
52.65%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.97%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
35.94%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
12.85%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
17.94%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
32.42%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
30.91%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.